Bicycle Therapeutics (NASDAQ:BCYC) Given Equal Weight Rating at Stephens

Stephens reissued their equal weight rating on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a research note released on Wednesday,Benzinga reports. Stephens currently has a $15.00 price target on the stock.

BCYC has been the subject of several other research reports. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. JMP Securities cut their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. B. Riley cut their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Finally, HC Wainwright restated a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $33.25.

Bicycle Therapeutics Stock Down 2.7 %

BCYC stock opened at $13.20 on Wednesday. Bicycle Therapeutics has a 52-week low of $12.17 and a 52-week high of $28.67. The firm has a market cap of $911.46 million, a P/E ratio of -4.01 and a beta of 0.92. The company’s 50-day simple moving average is $16.92 and its 200-day simple moving average is $21.34.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics’s revenue for the quarter was down 50.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.26) earnings per share. On average, analysts anticipate that Bicycle Therapeutics will post -3.05 earnings per share for the current fiscal year.

Insider Activity at Bicycle Therapeutics

In other news, Director Bros. Advisors Lp Baker purchased 985,397 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was acquired at an average price of $13.76 per share, for a total transaction of $13,559,062.72. Following the acquisition, the director now directly owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. This represents a 11.52 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,933 shares of company stock valued at $549,501. 8.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

Large investors have recently modified their holdings of the business. Avior Wealth Management LLC purchased a new stake in Bicycle Therapeutics in the 4th quarter valued at about $57,000. JPMorgan Chase & Co. raised its stake in shares of Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after acquiring an additional 1,782 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter worth approximately $10,028,000. Geode Capital Management LLC boosted its position in shares of Bicycle Therapeutics by 79.3% during the 3rd quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock worth $868,000 after purchasing an additional 16,958 shares during the period. Finally, Jane Street Group LLC increased its holdings in Bicycle Therapeutics by 35.7% in the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock valued at $457,000 after purchasing an additional 5,310 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.